Literature DB >> 27325918

The evidence on trial: cholesterol lowering and cancer.

A M Tonkin1, A Forbes1, S J Haas1.   

Abstract

Entities:  

Year:  2009        PMID： 27325918      PMCID： PMC4898325          DOI： 10.1136/ha.2008.000133

Source DB:  PubMed          Journal:  Heart Asia        ISSN： 1759-1104


× No keyword cloud information.
  49 in total

Review 1.  Potential anticancer effects of statins: fact or fiction?

Authors:  Varsha Kaushal; Manish Kohli; Paulette Mehta; Jawahar L Mehta
Journal:  Endothelium       Date:  2003

2.  The risk of cancer in users of statins.

Authors:  Matthijs R Graaf; Annette B Beiderbeck; Antoine C G Egberts; Dick J Richel; Henk-Jan Guchelaar
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

3.  Lovastatin-induced apoptosis in human melanoma cell lines.

Authors:  Yiqun G Shellman; Deborah Ribble; Leslie Miller; John Gendall; Kayleen Vanbuskirk; Desiree Kelly; David A Norris; Robert P Dellavalle
Journal:  Melanoma Res       Date:  2005-04       Impact factor: 3.599

4.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

5.  Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.

Authors: 
Journal:  Lancet       Date:  2002-04-20       Impact factor: 79.321

6.  Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).

Authors:  Timo E Strandberg; Kalevi Pyörälä; Thomas J Cook; Lars Wilhelmsen; Ole Faergeman; Gudmundur Thorgeirsson; Terje R Pedersen; John Kjekshus
Journal:  Lancet       Date:  2004 Aug 28-Sep 3       Impact factor: 79.321

7.  Analyses of cancer data from three ezetimibe trials.

Authors:  Richard Peto; Jonathan Emberson; Martin Landray; Colin Baigent; Rory Collins; Robert Clare; Robert Califf
Journal:  N Engl J Med       Date:  2008-09-02       Impact factor: 91.245

Review 8.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

9.  Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.

Authors:  Christopher P Cannon; Robert P Giugliano; Michael A Blazing; Robert A Harrington; John L Peterson; Christine McCrary Sisk; John Strony; Thomas A Musliner; Carolyn H McCabe; Enrico Veltri; Eugene Braunwald; Robert M Califf
Journal:  Am Heart J       Date:  2008-09-02       Impact factor: 4.749

10.  Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia.

Authors:  Gerd Assmann; Frank Kannenberg; Dena R Ramey; Thomas A Musliner; Stephen W Gutkin; Enrico P Veltri
Journal:  Curr Med Res Opin       Date:  2008-01       Impact factor: 2.580
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.